PolitiKit

Consultant In effect since Sep 2, 2026

Consultant Julia Parsons of Hill & Knowlton

Consultant lobbyists

• Julia Parsons Former public office holder

  Formerly Director of Policy, MP Michelle Rempel Garner, Parliament of Canada (2022–2023)

  Formerly Operations Manager, MP Michelle Rempel Garner, Parliament of Canada (2020–2022)

  Formerly Executive Assistant, MP Michelle Rempel Garner, Parliament of Canada (2017–2020)

  Formerly Research Assistant, MP Michelle Rempel Garner, Parliament of Canada (2016–2017)

Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Canada Economic Development for Quebec Regions, Canada Foundation for Innovation, Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Canadian Northern Economic Development Agency (CanNor), Competition Bureau Canada (COBU), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), International Development Research Centre (IDRC), National Defence (DND), National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (11)Hide details

• Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
• Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
• Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
• Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
• Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
• Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
• Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
• Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
• Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework
• Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
• Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.

Registration 956549-387731-1. Look it up in the official Registry